Bryan Szeglin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bryan Szeglin has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Philip B. Paty
25 shared publications- Leonard B. Saltz
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
24 shared publications Chao Wu
23 shared publicationsAndrea Cercek
22 shared publicationsRona Yaeger
22 shared publicationsGarrett M. Nash
21 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
Malignant Ascites Harbor Immune Niche with IL10-Enriched Effector Dysfunction and Persistent Cancer-Binding IgG
Malignant ascites provide a window into cancer–immune interactions in the peritoneal cavity. Using cytometry by time of flight, we analyzed ascitic immune cells collected from patients with advanced gastrointestinal cancers and nonmalignant forms of hepatitis (NMH) and healthy-control peripheral blood mononuclear cells (HC PBMC). Compositionally, ascitic immune cells shared a myeloid-rich, B cell– and naïve T cell–low signature relative to HC PBMCs. Underneath the shared ascitic compositional signature, three major functional immunophenotypes emerged in response to exogenous stimulation along a suppressive to cytotoxic axis, aligning with Luminex measurements of ascitic cytokine levels: IL10-enriched, nonpolarized, and granzyme B (GZMB)–enriched. In our cohort, the IL10-enriched functional immunophenotype was exclusive to samples from patients with cancer whereas the GZMB-enriched response was dominated by NMH samples. Ascites from patients with pancreatic ductal adenocarcinoma (PDAC) contained a persistent anticancer humoral response characterized by IgG that bound to autologous ascitic PDAC cells and multiple allogeneic PDAC cell lines. Significance: During the escape phase of cancer immunoediting, humoral immune recognition of cancer cells may persist within malignant ascites despite impaired cellular cytotoxic immunity in patients with advanced gastrointestinal cancers.
- 13 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
Open AccessMalignant Ascites Harbor Immune Niche with IL10-Enriched Effector Dysfunction and Persistent Cancer-Binding IgG
Malignant ascites provide a window into cancer–immune interactions in the peritoneal cavity. Using cytometry by time of flight, we analyzed ascitic immune cells collected from patients with advanced gastrointestinal cancers and nonmalignant forms of hepatitis (NMH) and healthy-control peripheral blood mononuclear cells (HC PBMC). Compositionally, ascitic immune cells shared a myeloid-rich, B cell– and naïve T cell–low signature relative to HC PBMCs. Underneath the shared ascitic compositional signature, three major functional immunophenotypes emerged in response to exogenous stimulation along a suppressive to cytotoxic axis, aligning with Luminex measurements of ascitic cytokine levels: IL10-enriched, nonpolarized, and granzyme B (GZMB)–enriched. In our cohort, the IL10-enriched functional immunophenotype was exclusive to samples from patients with cancer whereas the GZMB-enriched response was dominated by NMH samples. Ascites from patients with pancreatic ductal adenocarcinoma (PDAC) contained a persistent anticancer humoral response characterized by IgG that bound to autologous ascitic PDAC cells and multiple allogeneic PDAC cell lines. Significance: During the escape phase of cancer immunoediting, humoral immune recognition of cancer cells may persist within malignant ascites despite impaired cellular cytotoxic immunity in patients with advanced gastrointestinal cancers.
- 14 August 2026
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 69 (11) , 2639-2648
Short- Versus Long-Course Radiation in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Propensity-Matched National Cancer Database Analysis
BACKGROUND: Locally advanced rectal cancer is treated with total neoadjuvant therapy, which consists of neoadjuvant chemotherapy, radiation, and surgery. The comparative efficacy of long- and short-course radiotherapy within total neoadjuvant therapy remains uncertain. OBJECTIVE: Compare overall survival and pathological outcomes between patients treated with long- or short-course radiation as components of total neoadjuvant therapy. DESIGN: Retrospective cohort study. SETTINGS: National Cancer Database, 2018 to 2023. PATIENTS: Adults with clinical stage II or III rectal adenocarcinoma treated with neoadjuvant chemotherapy and radiation followed by radical surgical resection. MAIN OUTCOME MEASURES: Overall survival and pathological outcomes in a propensity score–matched cohort comparing long- and short-course radiation. RESULTS: A total of 12,462 patients met inclusion criteria; 10,740 patients (86.2%) received long-course radiation, and 1722 patients (13.8%) received short-course radiation. After 1:1 propensity score matching, 1721 patients per group were identified. Overall survival at 48 months did not differ (log-rank, p = 0.397). There were no differences in pathological complete response rate, pathological tumor stage, tumor downstaging, or pathological nodal stage. The long-course radiotherapy group had higher nodal downstaging (66.5% vs 62.7%; p = 0.023) and a nonsignificant trend toward lower nodal disease (N0 73.9% vs 70.7%, N1 21.5% vs 23.3%, and N2 4.6 vs 6.0%, respectively; p = 0.062). LIMITATIONS: Residual confounding from unmeasured clinical and treatment details is possible. This cohort was restricted to patients who underwent resection. CONCLUSIONS: Among patients with locally advanced rectal cancer who are treated with total neoadjuvant therapy and radical resection, long- and short-course radiotherapy had similar overall survival, but long-course radiotherapy patients had higher rates of nodal downstaging. These findings support the use of either long- or short-course radiotherapy regimens when planned resection is intended, but the clinical significance of differences in nodal downstaging remains uncertain. See Video Abstract. RADIOTERAPIA DE CORTA DURACIÓN versus DE LARGA DURACIÓN EN LA TERAPIA NEOADYUVANTE TOTAL PARA EL CÁNCER DE RECTO LOCALMENTE AVANZADO: UN ANÁLISIS DE LA BASE DE DATOS NACIONAL SOBRE CÁNCER CON EMPAREJAMIENTO POR PROPENSIÓN: ANTECEDENTES: El cáncer de recto localmente avanzado se trata con terapia neoadyuvante total, que consiste en quimioterapia neoadyuvante, radioterapia y cirugía. La eficacia comparativa de la radioterapia de ciclo largo y corto dentro de la terapia neoadyuvante total sigue siendo incierta. OBJETIVO: Comparar la supervivencia global y los resultados patológicos entre pacientes tratados con radioterapia de ciclo largo o corto como componentes de la terapia neoadyuvante total. DISEÑO: Estudio de cohorte retrospectivo. ÁMBITO: Base de datos nacional de cáncer, 2018 a 2023. PACIENTES: Adultos con adenocarcinoma de recto en estadio clínico II o III tratados con quimioterapia neoadyuvante y radioterapia seguida de resección quirúrgica radical. PRINCIPALES MEDIDAS DE RESULTADO: Supervivencia global y resultados patológicos en una cohorte emparejada por puntuación de propensión que compara la radioterapia de ciclo largo y corto. RESULTADOS: Un total de 12.462 pacientes cumplieron los criterios de inclusión; 10.740 (86,2 %) recibieron radioterapia de ciclo largo y 1.722 (13,8 %) recibieron radioterapia de ciclo corto. Tras el emparejamiento por puntuación de propensión 1:1, se identificaron 1.721 pacientes por grupo. La supervivencia global a los 48 meses no presentó diferencias significativas (log rank p = 0,397). No se observaron diferencias en la tasa de respuesta patológica completa, el estadio tumoral patológico, la reducción del estadio tumoral ni el estadio ganglionar patológico. El grupo de radioterapia de ciclo largo presentó una mayor reducción del estadio ganglionar (66,5 % frente a 62,7 %, p = 0,023) y una tendencia no significativa hacia una menor afectación ganglionar (N0 73,9% frente a 70,7 %, N1 21,5 % frente a 23,3 % y N2 4,6 % frente a 6,0 %, respectivamente, p = 0,062). LIMITACIONES: Es posible que exista confusión residual debido a detalles clínicos y de tratamiento no medidos. Esta cohorte se limitó a pacientes sometidos a resección. CONCLUSIONES: Entre los pacientes con cáncer de recto localmente avanzado tratados con terapia neoadyuvante total y resección radical, la radioterapia de ciclo largo y corto tuvo una supervivencia global similar, pero los pacientes con radioterapia de ciclo largo presentaron mayores tasas de reducción del estadio ganglionar. Estos hallazgos respaldan el uso de regímenes de radioterapia de ciclo largo o corto cuando se planifica una resección, pero la relevancia clínica de las diferencias en la reducción del estadio ganglionar sigue siendo incierta. (AI-generated translated )
- 14 August 2026
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 69 (11) , 2639-2648
Short- Versus Long-Course Radiation in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Propensity-Matched National Cancer Database Analysis
BACKGROUND: Locally advanced rectal cancer is treated with total neoadjuvant therapy, which consists of neoadjuvant chemotherapy, radiation, and surgery. The comparative efficacy of long- and short-course radiotherapy within total neoadjuvant therapy remains uncertain. OBJECTIVE: Compare overall survival and pathological outcomes between patients treated with long- or short-course radiation as components of total neoadjuvant therapy. DESIGN: Retrospective cohort study. SETTINGS: National Cancer Database, 2018 to 2023. PATIENTS: Adults with clinical stage II or III rectal adenocarcinoma treated with neoadjuvant chemotherapy and radiation followed by radical surgical resection. MAIN OUTCOME MEASURES: Overall survival and pathological outcomes in a propensity score–matched cohort comparing long- and short-course radiation. RESULTS: A total of 12,462 patients met inclusion criteria; 10,740 patients (86.2%) received long-course radiation, and 1722 patients (13.8%) received short-course radiation. After 1:1 propensity score matching, 1721 patients per group were identified. Overall survival at 48 months did not differ (log-rank, p = 0.397). There were no differences in pathological complete response rate, pathological tumor stage, tumor downstaging, or pathological nodal stage. The long-course radiotherapy group had higher nodal downstaging (66.5% vs 62.7%; p = 0.023) and a nonsignificant trend toward lower nodal disease (N0 73.9% vs 70.7%, N1 21.5% vs 23.3%, and N2 4.6 vs 6.0%, respectively; p = 0.062). LIMITATIONS: Residual confounding from unmeasured clinical and treatment details is possible. This cohort was restricted to patients who underwent resection. CONCLUSIONS: Among patients with locally advanced rectal cancer who are treated with total neoadjuvant therapy and radical resection, long- and short-course radiotherapy had similar overall survival, but long-course radiotherapy patients had higher rates of nodal downstaging. These findings support the use of either long- or short-course radiotherapy regimens when planned resection is intended, but the clinical significance of differences in nodal downstaging remains uncertain. See Video Abstract. RADIOTERAPIA DE CORTA DURACIÓN versus DE LARGA DURACIÓN EN LA TERAPIA NEOADYUVANTE TOTAL PARA EL CÁNCER DE RECTO LOCALMENTE AVANZADO: UN ANÁLISIS DE LA BASE DE DATOS NACIONAL SOBRE CÁNCER CON EMPAREJAMIENTO POR PROPENSIÓN: ANTECEDENTES: El cáncer de recto localmente avanzado se trata con terapia neoadyuvante total, que consiste en quimioterapia neoadyuvante, radioterapia y cirugía. La eficacia comparativa de la radioterapia de ciclo largo y corto dentro de la terapia neoadyuvante total sigue siendo incierta. OBJETIVO: Comparar la supervivencia global y los resultados patológicos entre pacientes tratados con radioterapia de ciclo largo o corto como componentes de la terapia neoadyuvante total. DISEÑO: Estudio de cohorte retrospectivo. ÁMBITO: Base de datos nacional de cáncer, 2018 a 2023. PACIENTES: Adultos con adenocarcinoma de recto en estadio clínico II o III tratados con quimioterapia neoadyuvante y radioterapia seguida de resección quirúrgica radical. PRINCIPALES MEDIDAS DE RESULTADO: Supervivencia global y resultados patológicos en una cohorte emparejada por puntuación de propensión que compara la radioterapia de ciclo largo y corto. RESULTADOS: Un total de 12.462 pacientes cumplieron los criterios de inclusión; 10.740 (86,2 %) recibieron radioterapia de ciclo largo y 1.722 (13,8 %) recibieron radioterapia de ciclo corto. Tras el emparejamiento por puntuación de propensión 1:1, se identificaron 1.721 pacientes por grupo. La supervivencia global a los 48 meses no presentó diferencias significativas (log rank p = 0,397). No se observaron diferencias en la tasa de respuesta patológica completa, el estadio tumoral patológico, la reducción del estadio tumoral ni el estadio ganglionar patológico. El grupo de radioterapia de ciclo largo presentó una mayor reducción del estadio ganglionar (66,5 % frente a 62,7 %, p = 0,023) y una tendencia no significativa hacia una menor afectación ganglionar (N0 73,9% frente a 70,7 %, N1 21,5 % frente a 23,3 % y N2 4,6 % frente a 6,0 %, respectivamente, p = 0,062). LIMITACIONES: Es posible que exista confusión residual debido a detalles clínicos y de tratamiento no medidos. Esta cohorte se limitó a pacientes sometidos a resección. CONCLUSIONES: Entre los pacientes con cáncer de recto localmente avanzado tratados con terapia neoadyuvante total y resección radical, la radioterapia de ciclo largo y corto tuvo una supervivencia global similar, pero los pacientes con radioterapia de ciclo largo presentaron mayores tasas de reducción del estadio ganglionar. Estos hallazgos respaldan el uso de regímenes de radioterapia de ciclo largo o corto cuando se planifica una resección, pero la relevancia clínica de las diferencias en la reducción del estadio ganglionar sigue siendo incierta. (AI-generated translated )
- Open Access
- 9 December 2023
- Published by BMJ in eGastroenterology
- Vol. 1 (2) , e100017
Pioneering use of genetic analysis for CDH1 to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer
Worldwide, gastric cancer results in significant morbidity and mortality. Ten per cent of patients with gastric cancer have a strong family history of the disease. CDH1 (E-cadherin) has been identified as a key gene whose mutation leads to hereditary diffuse gastric cancer. We overviewed 33 articles with prophylactic total gastrectomy and assessed the outcomes and benefits. Families with mutations in CDH1 may benefit from early prophylactic total gastrectomy. Dr Mark Duncan has applied his experience as a high-volume gastric cancer surgeon to treat not only individual patients, but several generations of patients within a family. This use of prophylactic total gastrectomy is well tolerated by patients and prevents the future development of gastric cancer.
- 9 December 2023
- Published by BMJ in eGastroenterology
- Vol. 1 (2) , e100017
Open AccessPioneering use of genetic analysis for CDH1 to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer
Worldwide, gastric cancer results in significant morbidity and mortality. Ten per cent of patients with gastric cancer have a strong family history of the disease. CDH1 (E-cadherin) has been identified as a key gene whose mutation leads to hereditary diffuse gastric cancer. We overviewed 33 articles with prophylactic total gastrectomy and assessed the outcomes and benefits. Families with mutations in CDH1 may benefit from early prophylactic total gastrectomy. Dr Mark Duncan has applied his experience as a high-volume gastric cancer surgeon to treat not only individual patients, but several generations of patients within a family. This use of prophylactic total gastrectomy is well tolerated by patients and prevents the future development of gastric cancer.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids
Identifying colorectal cancer patient populations responsive to chemotherapy or chemoradiation therapy before surgery remains a challenge. Recently validated mouse protocols for organoid irradiation employ the single hit multi-target (SHMT) algorithm, which yields a single value, the D0, as a measure of inherent tissue radiosensitivity. Here, we translate these protocols to human tissue to evaluate radioresponsiveness of patient-derived organoids (PDO) generated from normal human intestines and rectal tumors of patients undergoing neoadjuvant therapy. While PDOs from adenomas with a logarithmically expanded Lgr5+ intestinal stem cell population retain the radioresistant phenotype of normal colorectal PDOs, malignant transformation yields PDOs from a large patient subpopulation displaying marked radiosensitivity due to reduced homologous recombination–mediated DNA repair. A proof-of-principle pilot clinical trial demonstrated that rectal cancer patient responses to neoadjuvant chemoradiation, including complete response, correlate closely with their PDO D0 values. Overall, upon transformation to colorectal adenocarcinoma, broad radiation sensitivity occurs in a large subset of patients that can be identified using SHMT analysis of PDO radiation responses.Significance:Analysis of inherent tissue radiosensitivity of patient-derived organoids may provide a readout predictive of neoadjuvant therapy response to radiation in rectal cancer, potentially allowing pretreatment stratification of patients likely to benefit from this approach.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids
Identifying colorectal cancer patient populations responsive to chemotherapy or chemoradiation therapy before surgery remains a challenge. Recently validated mouse protocols for organoid irradiation employ the single hit multi-target (SHMT) algorithm, which yields a single value, the D0, as a measure of inherent tissue radiosensitivity. Here, we translate these protocols to human tissue to evaluate radioresponsiveness of patient-derived organoids (PDO) generated from normal human intestines and rectal tumors of patients undergoing neoadjuvant therapy. While PDOs from adenomas with a logarithmically expanded Lgr5+ intestinal stem cell population retain the radioresistant phenotype of normal colorectal PDOs, malignant transformation yields PDOs from a large patient subpopulation displaying marked radiosensitivity due to reduced homologous recombination–mediated DNA repair. A proof-of-principle pilot clinical trial demonstrated that rectal cancer patient responses to neoadjuvant chemoradiation, including complete response, correlate closely with their PDO D0 values. Overall, upon transformation to colorectal adenocarcinoma, broad radiation sensitivity occurs in a large subset of patients that can be identified using SHMT analysis of PDO radiation responses.Significance:Analysis of inherent tissue radiosensitivity of patient-derived organoids may provide a readout predictive of neoadjuvant therapy response to radiation in rectal cancer, potentially allowing pretreatment stratification of patients likely to benefit from this approach.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
Supplementary Methods and Supplementary Table 1
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
Supplementary Methods and Supplementary Table 1
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Kaplan-Meier graph with number of subjects at risk comparing (a) SMAD4, (b) TIL, and (c) PLA status, separately, as well as (d) SMAD4 and TIL, and (e) SMAD4 and PLA, together, with recurrence-free survival (RFS) among only the MMR-proficient patients.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Kaplan-Meier graph with number of subjects at risk comparing (a) SMAD4, (b) TIL, and (c) PLA status, separately, as well as (d) SMAD4 and TIL, and (e) SMAD4 and PLA, together, with recurrence-free survival (RFS) among only the MMR-proficient patients.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Kaplan-Meier graphs in the validation cohort with number of subjects at risk showing colorectal cancer-specific survival according to SMAD4 status.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Kaplan-Meier graphs in the validation cohort with number of subjects at risk showing colorectal cancer-specific survival according to SMAD4 status.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Kaplan-Meier graphs with number of subjects at risk comparing recurrence-free survival (RFS) by (a) TIL status, or (b) PLA status, with arrows indicating patients whose tumors were also SMAD4 loss.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Kaplan-Meier graphs with number of subjects at risk comparing recurrence-free survival (RFS) by (a) TIL status, or (b) PLA status, with arrows indicating patients whose tumors were also SMAD4 loss.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Distribution of colorectal cancer cases according to SMAD4 expression status and immune response to the tumor in validation cohort
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Distribution of colorectal cancer cases according to SMAD4 expression status and immune response to the tumor in validation cohort